Personalis reports FY24 revenue $84.6M (+15% YoY); provides FY25 guidance with $80-90M revenue, net loss ~$85M

Personalis, Inc.

2024-FY EPS reported -$1.37 revenue$84,614,000

FY24 revenue $84.6M (+15% YoY); net loss $81.3M vs $108.3M in FY23; cash $185M including $50M Merck investment.
Q4 revenue $16.8M (-15% YoY); delivered 1,441 molecular tests in Q4 (+52% QoQ); FY24 tests 3,285 vs 177 in FY23.
Guidance: FY25 revenue $80-90M, gross margin 21-23%, net loss ~$85M, cash usage $75-80M (up from $47M in FY24).
Business highlights: submitted for Medicare coverage in early-stage breast cancer; multi-year Moderna extension; expanded Tempus deal.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.